PRESS RELEASE
09 November 2026

BioUK acquires certain key assets of SEHTA to strengthen support for life science SMEs across the UK

- *Asset acquisition combines BioUK's strength in biotech and therapeutics with SEHTA's MedTech and HealthTech expertise, covering the full breadth of life science SMEs*
- *Enhances BioUK's support offerings with SEHTA's broad membership network and competencies in market access and grant-funding consultancy*

Oxford and London, UK, 9 November 2026: BioUK Ltd., the not-for-profit membership organisation focused on catalysing success in UK life sciences, today announced that it has acquired certain key assets of SEHTA (Science and Engineering Health Technologies Alliance) through an asset purchase agreement.

Established thirty years ago, BioUK provides practical help and support to the life science ecosystem, with a core focus on R&D SMEs. The organisation aims to create connections, save its members time & money, and help secure investment through a portfolio of tailored events and services. The acquisition of selected assets from SEHTA aligns with BioUK's mission and creates the opportunity to expand the organisation's membership base as well as broadening BioUK's support offerings in the areas of market access and non-dilutive investment support.

Formed in 2005, SEHTA represents a global network of more than 1,200 members working to drive innovation in healthcare. The organisation has built a reputation for supporting MedTech and HealthTech companies in their journey from concept to commercialisation through expert business support services. SEHTA's close relationships with the NHS and expertise in health economics enable companies to better navigate the pathway into the service through strategic economic and market access advice, alongside grant writing support.

Neil Roberts (SEHTA's Managing Director) and Clare Ansett (Operations Manager) will become part of BioUK's transition team to support those SEHTA members who would benefit from transferring over to BioUK membership and in supporting the relationships with the previous SEHTA expert associate network. The SEHTA brand will be wholly absorbed and will operate under the BioUK brand.

Stuart Rose, CEO of BioUK, said*: "The integration of some of SEHTA's key assets is an important strategic move for BioUK, and we're delighted to welcome its members to the BioUK community. Bringing those assets under the BioUK brand is an opportunity to expand beyond our biotech and therapeutics roots, widening our SME ecosystem and, through incorporating SEHTA's expertise, allowing us to better fulfil our mission to catalyse success across the entire life science sector. We will be hosting a series of new membership onboarding events during November, providing an opportunity for the SEHTA community to meet us as a team and explore how we can support their growth journey."*

Neil Roberts, MD of SEHTA said: *"For twenty years, SEHTA has helped MedTech and HealthTech SMEs successfully navigate the path from concept to commercialisation, and I'm proud of the community we've built. This asset transfer to BioUK is a real step forward for our members. They gain access to a broader nationwide network, industry leading events, more investor connections, and significant savings through BioUK's purchasing consortium, while the market access and grant-funding expertise they value carries on. Our MedTech and HealthTech knowledge will now be included to make BioUK the prominent membership organisation within the life science sector. We look forward to supporting our members through the transition and helping them make the most of the wider benefits BioUK offers."*

To find out more about BioUK and its mission to catalyse success in life sciences, please visit: biouk.com.

ENDS

Notes to editors:



Stuart Rose, CEO, BioUK



Neil Roberts, MD, SEHTA

For a high-resolution image, please contact Zyme Communications

Media enquiries

Zyme Communications
Lorna Cuddon
Tel: +44 (0) 7811996942
Email: lorna.cuddon@zymecommunications.com

BioUK
Sarah Walker, Executive Assistant
Email: sarah.walker@biouk.com

To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please click here.

About BioUK® www.biouk.com
BioUK (formerly known as OBN), is a not-for-profit member network focused on catalysing success in life sciences. Offering practical help and support to the life science ecosystem (particularly SMEs and micro-companies), BioUK aims to help create connections, save time & money and secure investment through a portfolio of tailored events and services.

BioUK was founded in 1996 as the Oxfordshire Bioscience Network. Now comprising c.530 member companies from across the UK life science sector, BioUK supports growth through access to an

extensive support ecosystem of investors, pharma companies, science parks and professional service organisations.

BioUK hosts around 50 industry events each year, including BioTrinity®, BioSeed® and BioForward, as well as specialist networking and knowledge-sharing events such as the BioTuesday, BioUK Breakfast meetings and the BioLearn® series. Alongside its event portfolio, BioUK provides a range of additional support for members, including its Purchasing Consortium, BioRaise® investment support service and BioUK coaching for emerging entrepreneurs and early-stage company leaders. BioUK members are able to access the organisation's Investment & Tax Advisory Group (ITAG) for regular financial updates and commentary, as well as the Partner4Pharma consultancy services for pharma business development, asset scouting and partnering.

For more information, visit our website and follow us on LinkedIn (@BioUK).

About SEHTA www.sehta.co.uk

SEHTA (Science and Engineering Health Technologies Alliance) was founded in 2005 and has 1,200 members comprising MedTech/HealthTech (MTHT) SMEs and associated expert service providers. It offers tailored business support through an established and highly flexible associate expert network to optimise the journey for MTHT SMEs from concept to market access.

BioUK will create a MedTech / HealthTech advisory board, calling on expertise within the SEHTA non-executive Board to optimise knowledge retention.

The Asset Purchase Agreement is for specified assets of SEHTA and excludes liabilities.